Document Detail


Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses.
MedLine Citation:
PMID:  9018085     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Eighteen patients with facial actinic keratoses were treated with the retinoid fenretinide (4-HPR), applied topically twice-daily for 3 months. After 3 months of treatment, complete regression was observed in 56% and partial regression in 44% of cases. Eight patients relapsed within 3 months after drug discontinuation. Six months later, only two patients (11%) showed a treatment response (complete regression). Blood samples showed that 4-HPR was not absorbed and no local or distant adverse effects were observed. Baseline plasma retinol levels were lower than in healthy subjects, thus suggesting that reduced retinol levels might be involved in this pathology. These encouraging preliminary results suggest the need for further studies to evaluate the best dosage schedules and duration of 4-HPR topical application in actinic keratoses.
Authors:
D Moglia; F Formelli; G Baliva; A Bono; M Accetturi; M Nava; G De Palo
Related Documents :
3197445 - Steatocystoma multiplex treated with isotretinoin: a delayed response.
11527265 - Treatment of childhood phimosis with a moderately potent topical steroid.
16716165 - Endothelin-1 is significantly elevated in plasma of patients with vitiligo treated with...
7503575 - Photosensitivity associated with combined uv-b and calcipotriene therapy.
15817605 - Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic tot...
15531835 - Group a beta-hemolytic streptococcal bacteremia.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer letters     Volume:  110     ISSN:  0304-3835     ISO Abbreviation:  Cancer Lett.     Publication Date:  1996 Dec 
Date Detail:
Created Date:  1997-02-21     Completed Date:  1997-02-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  87-91     Citation Subset:  IM    
Affiliation:
Division of Diagnostic Oncology and Outpatient Department, Istituto Nazionale Tumori, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adult
Anticarcinogenic Agents / therapeutic use*
Facial Dermatoses / blood,  drug therapy*
Female
Fenretinide / therapeutic use*
Humans
Keratosis / blood,  drug therapy*
Male
Middle Aged
Precancerous Conditions / blood,  drug therapy*
Remission Induction
Vitamin A / blood
Chemical
Reg. No./Substance:
0/Anticarcinogenic Agents; 11103-57-4/Vitamin A; 65646-68-6/Fenretinide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331...
Next Document:  Induction of iNOS mRNA by interferon-gamma in epithelial cells is associated with growth arrest and ...